AU2001275165A1 - Treatment of side effects associated with alcohol consumption - Google Patents

Treatment of side effects associated with alcohol consumption

Info

Publication number
AU2001275165A1
AU2001275165A1 AU2001275165A AU7516501A AU2001275165A1 AU 2001275165 A1 AU2001275165 A1 AU 2001275165A1 AU 2001275165 A AU2001275165 A AU 2001275165A AU 7516501 A AU7516501 A AU 7516501A AU 2001275165 A1 AU2001275165 A1 AU 2001275165A1
Authority
AU
Australia
Prior art keywords
treatment
side effects
effects associated
alcohol consumption
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275165A
Inventor
Stefan Arver
Olaf Haglund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ashni Naturaceuticals Inc
Original Assignee
Ashni Naturaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashni Naturaceuticals Inc filed Critical Ashni Naturaceuticals Inc
Publication of AU2001275165A1 publication Critical patent/AU2001275165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
AU2001275165A 2000-06-01 2001-06-01 Treatment of side effects associated with alcohol consumption Abandoned AU2001275165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20878800P 2000-06-01 2000-06-01
US60208788 2000-06-01
PCT/US2001/017916 WO2001091759A1 (en) 2000-06-01 2001-06-01 Treatment of side effects associated with alcohol consumption

Publications (1)

Publication Number Publication Date
AU2001275165A1 true AU2001275165A1 (en) 2001-12-11

Family

ID=22776062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275165A Abandoned AU2001275165A1 (en) 2000-06-01 2001-06-01 Treatment of side effects associated with alcohol consumption

Country Status (2)

Country Link
AU (1) AU2001275165A1 (en)
WO (1) WO2001091759A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862163A1 (en) 2006-05-12 2007-12-05 Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG L-Carnitin for supression of crystallisation
EP2253307B1 (en) * 2006-05-12 2015-07-08 Verla-Pharm Arzneimittelfabrik Apotheker H.J. von Ehrlich GmbH & Co. KG L-Carnitin for supression of crystallisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1143906B (en) * 1980-12-24 1986-10-29 Sigma Tau Ind Farmaceuti TIOCARNITINE PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC USE
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
JP3792272B2 (en) * 1995-06-13 2006-07-05 株式会社 伊藤園 Metabolic promoter of acetic acid and acetone in the body
AT411958B8 (en) * 1998-11-19 2004-09-27 Jhs Privatstiftung REFRESHING DRINK TO INCREASE ALCOHOL DEGRADING CAPACITY

Also Published As

Publication number Publication date
WO2001091759A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
AU2001291859A1 (en) Use of copolycarbonates
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AUPQ877300A0 (en) Topical treatment of skin
AU2001268525A1 (en) Human kinases
AU2001277959A1 (en) Human kinases
AU2001288612A1 (en) Human kinases
AU2001238488A1 (en) Human kinases
AU2001227972A1 (en) Methods to treat alpha-1-antitrypsin deficiency
AUPR074500A0 (en) Treatment of t cell disorders
AU2002242904A1 (en) Skin treatment comprising alcohol spirit
AU2002231206A1 (en) Treatment of depression
AU2001260834A1 (en) The treatment of herpes
AU2001257422A1 (en) Use of d-chiro-inositol in the treatment of conditions associated with hypothalamic gene expression
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
AU2002227925A1 (en) Human beta-defensin-3
AU2002213174A1 (en) Treatment of apoptotic cell death
AU2001240069A1 (en) Production of lutein in microorganisms
AU2001241630A1 (en) Treatment of inflammation with p20
AU2001255573A1 (en) Human kinases
AU2002227352A1 (en) Human kinases
AU2001275165A1 (en) Treatment of side effects associated with alcohol consumption
AU2001281950A1 (en) Regulation of human thimet oligopeptidase-like enzyme
AU2001286052A1 (en) Improvements relating to water treatment
AU2001274080A1 (en) Regulation of human transketolase-like enzyme